B-cell targeted CAR-T cells

B-cell targeted CAR-T cells refer to a chimeric antigen receptor (CAR) T-cell therapy program developed by Beijing Boren Hospital for the treatment of mature B-cell lymphomas. This therapeutic approach involves the genetic modification of a patient's T cells to express CARs that specifically recognize B-cell surface antigens, most notably CD19 and CD22. The hospital's clinical strategy often utilizes these CAR-T cells either sequentially or as a cocktail to target multiple antigens, aiming to reduce the risk of relapse due to antigen escape. This cell therapy has demonstrated significant efficacy in clinical trials for patients with relapsed or refractory B-cell malignancies, including various subtypes of non-Hodgkin lymphoma.

Other names

B-cell targeted chimeric antigen receptor T-cells